HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sales Of Drug-Spiked Rhino Supplements Trouble FDA After Importer's Arrest

This article was originally published in The Rose Sheet

Executive Summary

FDA's consumer warning about "Rhino" brand male enhancement products "due to a recent rise in reported health issues" marks latest detected use of ED ingredients in products fraudulently labeled as supplements and latest example of businesses flouting s regulatory framework that allows sales of most supplements without any pre-market approval process. FDA also uses announcement to recommend consumers ask for a health care provider's advice before "using or considering using any product marketed as a dietary supplement."

You may also be interested in...

Another 'Rhino' Marketer Horned By US FDA About ED-Spiked Supplements

Warning letter says Empire Distributors sold product branded “Rhino Black 5K Plus” that FDA analysis found contained sildenafil and tadalafil. FDA officials found on its websites, including an Amazon.com storefront, supplements bearing others brands used for products previously found with ED ingredients, including "Black Mamba Premium,” “Libigrow,” ““Rhino 25K,” and “Stamina-Rx.”

FDA Closes Another Business Smuggling Drugs From China As Dietary Ingredients

Importer Pure Assay Ingredients, owners Lynn Chau and Bao Luu charged in seven-count indictment with conspiring to deceive US Customs with stimulants labeled as melatonin, sucralose or other dietary ingredients. Also charged are two Chinese citizens who worked for Pure Assay in Chengdu, China, to bring the illegal substances to the US.

FDA Could Stick With Current Advice On NDI Notifications, Old Ingredient Evidence

FDA has little priority, and limited resources available for finalizing its 2016 draft guidance on NDI notifications and for establishing a process that certifies dietary ingredients as being available before October 1994, says regulatory attorney Miriam Guggenheim.For both of those developments, she says, "I'm not holding my breath."

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts